Literature DB >> 10896915

Autoantibodies against the specific epitope of human tropomyosin(s) detected by a peptide based enzyme immunoassay in sera of patients with ulcerative colitis show antibody dependent cell mediated cytotoxicity against HLA-DPw9 transfected L cells.

S Sakamaki1, N Takayanagi, N Yoshizaki, S Hayashi, T Takayama, J Kato, K Kogawa, N Yamauchi, N Takemoto, A Nobuoka, T Ayabe, Y Kohgo, Y Niitsu.   

Abstract

BACKGROUND AND AIMS: Recent studies suggest that tropomyosin (TM) may act as a putative autoantigen in ulcerative colitis (UC). Recently, we identified, by computer homology analysis, a specific peptide (HIAEDADRK) in human TM that can bind to HLA-DPw9. The aim of this study was to investigate the presence of autoantibodies against this peptide in UC.
METHODS: Antibodies were measured by ELISA with a synthetic peptide in 20 healthy volunteers, 48 patients with UC, 26 with Crohn's disease (CD), eight with primary sclerosing cholangitis (PSC), and six with primary biliary cirrhosis (PBC). The functional significance of antibodies was investigated by antibody dependent cell mediated cytotoxicity (ADCC) against DPw9 transfected L cells using a standard (51)Cr release assay.
RESULTS: Optical density values (mean (SD)) of sera from patients with UC (1.40 (0. 52)) and PSC (1.65 (0.12)) were significantly higher than those from healthy volunteers (0.32 (0.28)) (p<0.05), CD (0.50 (0.34)) (p<0.05) and PBC (0.14 (0.09)) (p<0.05). Values in UC decreased with clinical improvement. The ADCC activity of UC sera correlated well with antibody titre against this synthetic peptide.
CONCLUSIONS: Anti-TM antibody was detected in UC sera by a specific peptide based ELISA with high reproducibility. This peptide may be an antigenic epitope of TM involved in the immunopathogenesis of UC and, perhaps, PSC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896915      PMCID: PMC1727987          DOI: 10.1136/gut.47.2.236

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

Review 1.  Speculations on mechanisms of HLA associations with autoimmune diseases and the specificity of "autoreactive" T lymphocytes.

Authors:  E Möller; J Böhme; M A Valugerdi; A Ridderstad; O Olerup
Journal:  Immunol Rev       Date:  1990-12       Impact factor: 12.988

Review 2.  Primary biliary cirrhosis.

Authors:  M M Kaplan
Journal:  N Engl J Med       Date:  1987-02-26       Impact factor: 91.245

3.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

4.  Immunogenicity of glucagon: determinants responsible for antibody binding and lymphocyte stimulation.

Authors:  G Senyk; D Nitecki; J W Goodman
Journal:  Science       Date:  1971-01-29       Impact factor: 47.728

5.  Cellular killing of microfilariae of Onchocerca volvulus: eosinophil and neutrophil-mediated immune serum-dependent destruction.

Authors:  B M Greene; H R Taylor; M Aikawa
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

6.  Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis.

Authors:  F Takahashi; K M Das
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

7.  Isolation and characterization of colonic tissue-bound antibodies from patients with idiopathic ulcerative colitis.

Authors:  K M Das; R Dubin; T Nagai
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

8.  Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology.

Authors:  R W Chapman; B A Arborgh; J M Rhodes; J A Summerfield; R Dick; P J Scheuer; S Sherlock
Journal:  Gut       Date:  1980-10       Impact factor: 23.059

9.  Association of the human lymphocyte-DR2 antigen with Japanese ulcerative colitis.

Authors:  H Asakura; M Tsuchiya; S Aiso; M Watanabe; K Kobayashi; T Hibi; K Ando; H Takata; S Sekiguchi
Journal:  Gastroenterology       Date:  1982-03       Impact factor: 22.682

10.  Autoantibodies in human ulcerative colitis.

Authors:  O BROBERGER; P PERLMANN
Journal:  J Exp Med       Date:  1959-11-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Vertebrate tropomyosin: distribution, properties and function.

Authors:  S V Perry
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

Review 2.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 3.  Autoantibodies and liver disease: uses and abuses.

Authors:  Marilyn V Zeman; Gideon M Hirschfield
Journal:  Can J Gastroenterol       Date:  2010-04       Impact factor: 3.522

4.  Autoimmunity in ulcerative colitis (UC): a predominant colonic mucosal B cell response against human tropomyosin isoform 5.

Authors:  E K Onuma; P S Amenta; K Ramaswamy; J J Lin; K M Das
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

5.  Effects of appendicectomy on the course of ulcerative colitis.

Authors:  J Cosnes; F Carbonnel; L Beaugerie; A Blain; D Reijasse; J-P Gendre
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

6.  Antibodies against hepatoma-derived growth factor and mucosal repair in ulcerative colitis.

Authors:  Hideji Nakamura; Kenya Yoshida; Kazuhiro Ikegame; Yoshihiko Kishima; Hirokazu Uyama; Hirayuki Enomoto
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

7.  Proctocolectomy for colon cancer associated with ulcerative colitis a few months after living donor liver transplantation for primary sclerosing cholangitis: report of a case.

Authors:  Takasuke Fukuhara; Akinori Egashira; Masakazu Imamura; Toru Ikegami; Eiji Oki; Yuji Soejima; Noriaki Sadanaga; Akinobu Taketomi; Takashi Yao; Masaru Morita; Yoshihiro Kakeji; Masazumi Tsuneyoshi; Yoshihiko Maehara
Journal:  Surg Today       Date:  2009-01-08       Impact factor: 2.549

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.